These findings demonstrate the importance of tumor-specific genetic alterations to reprogram the immune landscape in cancer and highlight a chronic myeloid cell inflammatory phenotype driven by CX3CL1 as an underlying characteristic and potential target for the treatment of ccRCC tumors. This evidence concerns the gene CX3CL1 and neoplasm.